Equibles does not estimate personal net worth.
Get an email with a short summary when Emergent BioSolutions Inc. publishes a filing, an earnings call transcript or a press release.
Get EBS alertsRichard S. Lindahl is recorded as CFO at Emergent BioSolutions Inc. (EBS). The newest filing on record that lists Richard S. Lindahl as CFO at Emergent BioSolutions Inc. (EBS) is dated March 20, 2026. The proxy statement of Emergent BioSolutions Inc. reports total compensation of $2,708,723 for Richard S. Lindahl in fiscal 2025, including a base salary of $662,020. Disclosed compensation is on record for 8 fiscal years. Richard S. Lindahl has spoken on 3 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on October 29, 2025. Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Daniel J. Abdun-Nabi (CEO, COO and Board Member), Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member) and 7 others.
“We're off to a strong start in the second half of 2025. Our third quarter revenue came in at $231 million, exceeding the upper end of our guidance range by $21 million, driven by sequential growth of NARCAN and the addition of 4 new contract modifications.”
“Emergent's second quarter results reflect continued strong execution and progress on our multiyear transformation plan. Our second quarter revenue came in at $141 million, exceeding the top end of our guidance range by $21 million.”
“And good afternoon everyone and thank you for joining the call. I'm thrilled to be joining my first earnings call as Emergent’s new CFO. There is a great deal going on here at Emergent and I look forward to working closely with my new colleagues in pursuit of our business objectives, as well as our mission and vision.”
Start not stated–present
Last confirmed March 20, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer | $662,020 | $2,708,723 |
| 2024 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer and Treasurer | $638,185 | $2,311,320 |
| 2023 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer and Treasurer | $613,850 | $2,178,980 |
| 2022 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer and Treasurer | $593,878 | $3,522,762 |
| 2021 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer and Treasurer | $577,357 | $2,197,585 |
| 2020 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer and Treasurer | $549,390 | $2,281,300 |
| 2019 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, ChiefFinancial Officerand Treasurer | $514,826 | $1,877,497 |
| 2018 | Emergent BioSolutions Inc. (EBS) | Executive Vice President, Chief Financial Officer and Treasurer | $365,393 | $1,612,453 |
